In conclusion, this phase II proof-of-concept study provides initial evidence that using a specific monoclonal antibody (CERC-002) to neutralize the LIGHT cytokine might provide therapeutic benefit, including reducing mortality rates, for patients with COVID-19–related ARDS and CRS. This evidence concerns the gene TNFSF14 and COVID-19.